Literature DB >> 2997242

Transforming growth factor (TGF) activity in human urine: synergism between TGF-beta and urogastrone.

D R Twardzik, S A Sherwin.   

Abstract

Human urine contains an acid and heat stable peptide with an apparent molecular weight of 8,000-10,000 that, in the presence of urogastrone (EGF), induces the anchorage-independent growth of nontransformed cells in semisolid media. This nonmitogenic growth-modulating activity does not compete with EGF for binding to EGF membrane receptor sites and can be resolved from EGF by high-performance liquid chromatography. The urine-derived growth factor has been purified more than 10,000-fold and shares many biochemical properties with and is functionally related to the B class of TGFs isolated from transformed cells and non-neoplastic tissues. The low molecular weight anchorage-independent growth-stimulating activity universally present in human urine is a result of the synergistic interaction of this urine-derived TGF-beta and urogastrone.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997242     DOI: 10.1002/jcb.240280407

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  3 in total

1.  Type 1 transforming growth factor beta: amplified expression and secretion of mature and precursor polypeptides in Chinese hamster ovary cells.

Authors:  L E Gentry; N R Webb; G J Lim; A M Brunner; J E Ranchalis; D R Twardzik; M N Lioubin; H Marquardt; A F Purchio
Journal:  Mol Cell Biol       Date:  1987-10       Impact factor: 4.272

2.  Autocrine transforming growth factor-{beta}1 activation mediated by integrin {alpha}V{beta}3 regulates transcriptional expression of laminin-332 in Madin-Darby canine kidney epithelial cells.

Authors:  Jose V Moyano; Patricia G Greciano; Mary M Buschmann; Manuel Koch; Karl S Matlin
Journal:  Mol Biol Cell       Date:  2010-09-15       Impact factor: 4.138

3.  Urinary epidermal growth factor concentrations in various human malignancies.

Authors:  A L Mattila; I Saario; L Viinikka; O Ylikorkala; J Perheentupa
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.